VendorMark said:For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.
I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.
VendorMark said:For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.
Agreed, and the size of the effect matters as much as its existence. Something real and small gets treated here as though it were real and decisive.
VendorMark said:For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.
That reframing is the part I needed. Taking it to my next appointment.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAdding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.
OP back with an update, since a thread like this is useless without one.
Follow-up — getting the denial reason in writing was the step that mattered. It named the criterion, and the criterion was a document I already had.